ArticleScientific reports2019
Optimization of the adipose-derived mesenchymal stem cell delivery time for radiation-induced lung fibrosis treatment in rats.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Immune checkpoint inhibitor-related pneumonitis: current advances and the putative role of mesenchymal stem cell therapy.Cell death & disease · 2026Review
- Adipose-derived stromal vascular fraction injection for radiation-induced bladder fibrosis: a first-in-human pilot study.Stem cells translational medicine · 2026Article
- Enhanced therapeutic efficacy of repeated bone marrow-derived MSC administration in a murine model of pulmonary fibrosis.Stem cell research & therapy · 2025Article
- Efficacy and Safety of Cell-Assisted Acellular Adipose Matrix Transfer for Volume Retention and Regeneration Compared to Hyaluronic Acid Filler Injection.Aesthetic plastic surgery · 2025Article
- Emerging delivery approaches for targeted pulmonary fibrosis treatment.Advanced drug delivery reviews · 2024Review
- Mesenchymal Stem Extracellular Vesicles in Various Respiratory Diseases: A New Opportunity.Journal of inflammation research · 2024Review
- Tissue fibrosis induced by radiotherapy: current understanding of the molecular mechanisms, diagnosis and therapeutic advances.Journal of translational medicine · 2023Review
- Reversal of Pulmonary Fibrosis: Human Umbilical Mesenchymal Stem Cells from Wharton's Jelly versus Human-Adipose-Derived Mesenchymal Stem Cells.International journal of molecular sciences · 2023Article
- Review
- Stem cell-based therapy for pulmonary fibrosis.Stem cell research & therapy · 2022Review
- Mesenchymal stem cells in radiation-induced lung injury: From mechanisms to therapeutic potential.Frontiers in cell and developmental biology · 2022Review
- Lung Pneumonitis and Fibrosis in Cancer Therapy: A Review on Cellular and Molecular Mechanisms.Current drug targets · 2022Review
- Mesenchymal Stem Cells and their Derived Exosomes Promote Malignant Phenotype of Polyploid Non-Small-Cell Lung Cancer Cells through AMPK Signaling Pathway.Analytical cellular pathology (Amsterdam) · 2022Article
- Therapeutic Applications of Mesenchymal Stem Cells in Idiopathic Pulmonary Fibrosis.Frontiers in cell and developmental biology · 2021Review
- Chronic Obstructive Pulmonary Disease and the Cardiovascular System: Vascular Repair and Regeneration as a Therapeutic Target.Frontiers in cardiovascular medicine · 2021Review
- Stem cells part of the innate and adaptive immune systems as a therapeutic for Covid-19.Communicative & integrative biology · 2021Review
- Adipose Stromal Cell-Secretome Counteracts Profibrotic Signals From IPF Lung Matrices.Frontiers in pharmacology · 2021Article
- Extracellular Vesicles for the Treatment of Radiation Injuries.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study attempts to identify the optimal time duration for the administration of Ad-MSCs, in order to maximize its therapeutic benefits, and compare the degree of fibrosis among three different administration time points using the RILF rat model system. Ad-MSCs were delivered to Sprague-Dawley rats through the tail vein at the following different time points after thorax irradiation: two hours, seven days, and two hours + seven days. Post Ad-MSCs transplantation and the histopathological analysis of the lungs were performed along with analysis of inflammatory cytokine levels, including interleukin (IL)-1, IL-2, IL-6, IL-10 and tumor necrosis factor-α (TNF-α). In particular, pro-fibrotic factors (TGF-β1 and α-SMA) were also evaluated in serum and lung tissues. In addition, it was also determined whether Ad-MSCs had any role in inhibiting the transition of type II alveolar epithelial cells into fibroblasts in the lungs of injured rats. The present results demonstrated that the intravenous delivery of Ad-MSCs twice at the 2-hour and 7-day (R + MSC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.